Xenetic Biosciences Inc.

Company Overview

Business Model: Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies to address difficult-to-treat cancers. The Company's primary proprietary technology is DNase, designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs) involved in cancer progression and resistance. Additionally, Xenetic Biosciences, Inc. has a proprietary drug delivery platform, PolyXen, which utilizes polysialic acid (PSA) to prolong drug half-life and improve stability of therapeutic peptides and proteins. The Company generates revenue primarily through royalty payments from an exclusive license arrangement of its PolyXen technology in the field of blood coagulation disorders. Xenetic Biosciences, Inc. does not currently have any products approved for commercial sale.

Market Position: Xenetic Biosciences, Inc. operates as an early-stage company within the highly competitive biotechnology and pharmaceutical industries, characterized by rapidly advancing technologies. The Company's DNase technology is focused on multi-billion-dollar oncology indications with significant unmet needs, including pancreatic ductal adenocarcinoma (PDAC) and colorectal carcinoma (CRC). PDAC has a high mortality rate with a five-year survival rate of approximately 13% overall and 2% for metastatic disease. CRC is the second most common cause of cancer death in the U.S., with a five-year survival rate of 13% for distant metastatic disease. The Company aims to improve response and overcome resistance to existing cancer therapies in these areas. The PolyXen platform competes with other drug delivery technologies such as PEGylation, Fc-fusion, albumin-fusion, HESylation, PASylation, and CTP-fusion. Many competitors possess significantly greater financial resources and expertise across research, development, manufacturing, and commercialization.

Recent Strategic Developments:

• Primary Focus: Advancing the systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally advanced or metastatic solid tumors, including colorectal carcinoma.
• University of Virginia (UVA) Collaboration: On December 21, 2023, Xenetic Biosciences, Inc. entered into a Research Funding and Material Transfer Agreement with UVA to advance its systemic DNase program. The Company holds an option to acquire an exclusive license to any new intellectual property arising from this research. The agreement was extended through December 2025 in November 2024, with UVA continuing to investigate DNase I combinations with immunotherapies in colorectal cancer models.
• Scripps Research Institute (Scripps Research) Collaboration: On March 17, 2023, Xenetic Biosciences, Inc. entered into a Research Funding and Option Agreement with Scripps Research, providing up to $0.9 million to fund pre-clinical development of its DNase technology. The Company has an option for a worldwide exclusive license to Scripps Research’s related intellectual property. The agreement was extended to October 31, 2024, and further extended on November 1, 2024, for an additional twelve months with up to approximately $400,000 in additional funding for continuing research focused on CAR T in vivo models.
• Belgian Volition SARL Limited (Volition) Collaboration: On August 2, 2022, Xenetic Biosciences, Inc. announced a research and development collaboration with Volition to develop NETs-targeted adoptive cell therapies for cancer, combining Volition’s Nu.Q® technology and Xenetic Biosciences, Inc.’s DNase-Armored CAR T platform. Volition funds the research program, and both parties will share proceeds from commercialization or licensing.
• Catalent Pharma Solutions LLC (Catalent) Agreement: On June 30, 2022, Xenetic Biosciences, Inc. entered into a Statement of Work with Catalent for cGMP manufacturing of its recombinant protein, Human DNase I.
• Internal Development Focus: During 2024, the Company's internal development efforts were primarily focused on the advancement of its DNase technology, with no active pursuit of XCART or PolyXen development.
• ErepoXen (PolyXen platform): While not pursuing internal clinical development, Xenetic Biosciences, Inc. is entertaining out-license opportunities. PJSC Pharmsynthez reported positive Phase II(b)/III data for Epolong (ErepoXen) in Russia in 2020, filed a registration dossier, and is addressing deficiencies. Serum Institute of India Limited conducted Phase I/II trials in India but is not actively pursuing the program.
• Orphan Drug Designation: Xenetic Biosciences, Inc. intends to pursue orphan drug designations and accelerated approval pathways for relevant oncology indications in both the U.S. and Europe.

Geographic Footprint: Xenetic Biosciences, Inc. is incorporated in Nevada and based in Framingham, Massachusetts. The Company operates through wholly-owned subsidiaries including Hesperix S.A., Xenetic Biosciences (U.K.) Limited, Lipoxen Technologies Limited, Xenetic Bioscience, Incorporated, and SymbioTec, GmbH. Its intellectual property strategy includes filing patents in major pharmaceutical markets globally, such as the U.S., U.K., Australia, Japan, Canada, South Korea, China, India, Russia, and certain European Union countries. Collaborations extend to Russia (PJSC Pharmsynthez) and India (Serum Institute of India Limited).

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: N/A (Revenue is solely royalty-based, no Cost of Goods Sold reported)
• Operating Margin: -168.16%
• Net Margin: -158.39%

Investment in Growth:

• R&D Expenditure: $3,288,332 (131.52% of revenue)
• Capital Expenditures: Not explicitly stated; no cash flows from investing activities reported.
• Strategic Investments:
  • University of Virginia: Approximately $0.4 million paid through December 31, 2024.
  • Scripps Research Institute: Approximately $0.9 million paid through December 31, 2024, with an additional $400,000 committed for continuing research.
  • Catalent Pharma Solutions LLC: Approximately $2.5 million paid through December 31, 2024, for cGMP manufacturing.

Business Segment Analysis

Xenetic Biosciences, Inc. manages its business as a single operating segment, focusing on pre-clinical research and development activities to advance its DNase technology.

Single Operating Segment

Financial Performance:

• Revenue: $2,500,284 (-1.6% YoY)
• Operating Margin: -168.16%
• Key Growth Drivers: The Company's revenue is primarily derived from royalty payments under a sublicense agreement with Takeda Pharmaceutical Co. Ltd. for its PolyXen technology. Future growth is dependent on the successful clinical development and commercialization of the DNase technology and other drug candidates, as well as the establishment of new strategic collaborations.

Product Portfolio:

• DNase Technology: This proprietary technology is designed to target NETs to improve outcomes of existing treatments, including immunotherapies, for difficult-to-treat cancers. It is currently in development for solid tumors, with an initial focus on pancreatic carcinoma and locally advanced or metastatic solid tumors, including colorectal carcinoma. The portfolio includes an early pre-clinical DNase-armored CAR T program.
• PolyXen Platform: An enabling drug delivery platform utilizing polysialic acid (PSA) to extend the half-life and potentially improve the stability of therapeutic peptides and proteins. It is out-licensed to Takeda Pharmaceutical Co. Ltd. for blood coagulation disorders, generating ongoing royalty revenue. ErepoXen, a polysialylated erythropoietin using PolyXen, is being developed by partners for anemia in chronic kidney disease, though Xenetic Biosciences, Inc. is not pursuing its clinical development internally.
• Other Technologies: XCART, OncoHist, and ImuXen are mentioned as proprietary technologies but were not actively pursued for development in 2024.

Market Dynamics:

• The DNase technology targets multi-billion-dollar indications such as PDAC and CRC, which have significant unmet medical needs and high mortality rates. The Company aims to address resistance to current therapies, including checkpoint inhibitors, chemotherapy, and radiotherapy.
• In PDAC, current standard treatments include Gemcitabine in combination with Abraxane or FOLFIRINOX, with NALIRIFOX recently approved for first-line metastatic PDAC. Second-line options are limited to Onivyde in combination with Fluorouracil and leucovorin.
• For metastatic CRC, chemotherapy remains the primary systemic treatment for the majority of patients (MSS/MMRp mCRC). Immune checkpoint inhibitors are used for MSI-H/dMMR mCRC, but a significant number of patients are resistant. The Company's DNase technology seeks to provide more effective therapeutic options, particularly where ICIs have shown limited benefit.
• The PolyXen platform operates in a competitive drug delivery market with various established and emerging technologies.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Xenetic Biosciences, Inc. did not repurchase any shares of its common stock during the quarter ended December 31, 2024.
• Dividend Payments: The Company has never declared or paid any cash dividends on its common stock or preferred stock. It currently intends to retain future earnings for business development and does not anticipate paying cash dividends in the foreseeable future.
• Dividend Yield: 0%
• Future Capital Return Commitments: None disclosed.

Balance Sheet Position:

• Cash and Equivalents: $6,165,568 (as of December 31, 2024)
• Total Debt: Not disclosed; no debt instruments are listed in the liabilities section.
• Net Cash Position: $6,165,568
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable as no debt is reported.

Cash Flow Generation:

• Operating Cash Flow: -$2,817,478 (for the year ended December 31, 2024)
• Free Cash Flow: Not explicitly stated, but given no cash flows from investing activities, it is approximately -$2,817,478.
• Cash Conversion Metrics: Not explicitly stated.

Operational Excellence

Production & Service Model: Xenetic Biosciences, Inc. operates as a virtual company, lacking internal manufacturing capabilities and in-house research facilities. Its operational philosophy is to leverage external expertise and resources. The Company relies on contract manufacturing organizations (CMOs) for the production of materials necessary for drug candidate development programs, such as Catalent Pharma Solutions LLC for Human DNase I recombinant protein. For research and development, it depends on contract research organizations (CROs), clinical investigators, and academic institutions (e.g., University of Virginia, Scripps Research Institute) to conduct and supervise clinical studies and advance its pipeline.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing: Catalent Pharma Solutions LLC - provides current Good Manufacturing Principles (cGMP) manufacturing services for the Company’s recombinant protein, Human DNase I.
• Research & Development:
  • University of Virginia - collaborates on advancing the systemic DNase program, including investigating combinations of DNase I with immunotherapies in colorectal cancer models.
  • Scripps Research Institute - provides pre-clinical development services for the DNase technology, including CAR T in vivo models and enhancing CAR T cell function.
  • Belgian Volition SARL Limited - a research and development collaboration to develop NETs-targeted adoptive cell therapies for cancer.
  • PJSC Pharmsynthez - a collaborative research and development license agreement for PolyXen and ImuXen technology in specific territories.
  • Serum Institute of India Limited - a collaborative research and development agreement for PolyXen technology (Polysialylated Erythropoietin) in predetermined territories.
• Technology Partners: CLS Therapeutics Ltd. - exclusive license and sublicense agreements for interventional DNase technology.

Facility Network:

• Administrative: Xenetic Biosciences, Inc. rents office space at an office share location in Framingham, Massachusetts, under a 6-month lease through March 31, 2025. A previously leased office space in Miami, Florida, was terminated in November 2024.
• Manufacturing: The Company relies entirely on third-party manufacturing facilities.
• Research & Development: The Company relies on the facilities and resources of its academic and contract research partners.

Operational Metrics:

• Total Employees: 2 full-time employees (as of December 31, 2024).
• Outside services and contract research organizations expense: $1,898,121 (2024) vs. $2,886,985 (2023).
• Salaries and wages (R&D): $562,571 (2024) vs. $417,952 (2023).

Market Access & Customer Relationships

Go-to-Market Strategy: Xenetic Biosciences, Inc. does not possess internal sales, marketing, or distribution capabilities. Its go-to-market strategy is predicated on leveraging collaboration partners for the development and potential commercialization of its drug candidates in the pharmaceutical marketplace. The Company intends to pursue orphan drug designations and accelerated approval pathways for relevant oncology indications in the U.S. and Europe to potentially expedite market entry.

Distribution Channels:

• Channel Partners: The Company relies on its strategic partners for market access and distribution. This includes Takeda Pharmaceutical Co. Ltd. for products utilizing the PolyXen technology, and potentially PJSC Pharmsynthez and Serum Institute of India Limited for ErepoXen in their respective licensed territories.

Customer Portfolio:

• Strategic Partnerships: Key relationships include Takeda Pharmaceutical Co. Ltd., Belgian Volition SARL Limited, Catalent Pharma Solutions LLC, Scripps Research Institute, University of Virginia, PJSC Pharmsynthez, and Serum Institute of India Limited.
• Customer Concentration: The Company's revenue is primarily derived from royalty payments from a single partner, Takeda Pharmaceutical Co. Ltd., indicating a concentration risk.

Geographic Revenue Distribution:

• Royalty revenue from Takeda Pharmaceutical Co. Ltd. is global in scope.
• Collaborations with PJSC Pharmsynthez cover Russia and Commonwealth of Independent States.
• Collaborations with Serum Institute of India Limited cover predetermined territories in India.
• The Company's strategic focus for its DNase oncology indications includes the U.S. and Europe.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and pharmaceutical industries are characterized by rapid technological advancements, intense competition, and a strong emphasis on proprietary products. The oncology treatment market is large and growing, attracting numerous new entrants. The development of pharmaceutical products is a highly speculative undertaking with a substantial degree of risk and a low success rate for bringing compounds to market. There is a significant unmet medical need in the specific cancer indications Xenetic Biosciences, Inc. is targeting, such as pancreatic ductal adenocarcinoma (PDAC) and colorectal carcinoma (CRC).

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• General: Xenetic Biosciences, Inc. faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions. Many of these entities possess significantly greater financial resources, development capabilities, and experience in preclinical testing, clinical trials, regulatory approvals, and marketing.
• Pancreatic Cancer: Current approved treatments include Gemcitabine in combination with Abraxane or FOLFIRINOX. NALIRIFOX (liposomal irinotecan) recently received FDA approval for first-line metastatic pancreatic adenocarcinoma. For second-line metastatic patients, Onivyde in combination with Fluorouracil and leucovorin is an approved regimen. Targeted therapies include Merck’s KEYTRUDA for MSI-H cancers (approximately 1% of cases) and Lynparza for BRCA mutated pancreatic cancer (approximately 7% of cases).
• Colorectal Cancer (mCRC): For microsatellite stable (MSS) and mismatch repair proficient (MMRp) mCRC patients (>90%), chemotherapy regimens (e.g., FOLFOX, CAPEOX, FOLFIRI, CAPIRI, FOLFIRINOX, FOLFOXIRI) often combined with biologics like bevacizumab, aflibercept, or ramucirumab, are standard. For MSI-H/dMMR mCRC patients (approximately 10%), immune checkpoint inhibitors (ICIs) such as Keytruda, Opdivo, and Yervoy are approved.
• PSA for Drug Delivery: Competing platforms include PEGylation, Fc-fusion, albumin-fusion, HESylation, PASylation, and CTP-fusion, offered by various pharmaceutical and biotechnology companies.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions in oncology and drug delivery could emerge. Competitors may develop products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive. Rapid regulatory approval for competitor products could establish strong market positions before Xenetic Biosciences, Inc. can enter the market. The increasing trend of insurers and third-party payors encouraging generic products also poses a competitive threat.

Competitive Response Strategy: Xenetic Biosciences, Inc.'s strategy involves focusing on its proprietary DNase technology to improve treatment outcomes and overcome resistance to existing cancer therapies. The Company intends to pursue orphan drug designations and accelerated approval pathways to potentially gain market advantages. It also relies on strategic collaborations to efficiently manage resources and advance its pipeline, leveraging partner-generated preclinical and clinical data for major markets.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Uncertain Commercial Potential: Difficulty in predicting the commercial potential and market size for new pharmaceutical products, which could significantly impact revenue and financial condition if market size is smaller than anticipated.
• Intense Competition: Operating in a rapidly evolving and highly competitive field, with many competitors possessing greater financial and development resources, potentially leading to new therapies that are more effective or render Xenetic Biosciences, Inc.'s products obsolete.
• Market Acceptance: Commercial success is contingent on acceptance by physicians, patients, and third-party payors, which may not materialize if products are not perceived as medically useful, cost-effective, or safe.
• Limited Patient Population: Initial market opportunities for drug candidates may be restricted to patients who are ineligible for or have failed prior treatments, potentially limiting the addressable market size.
• Healthcare Legislative Reform: Ongoing changes in healthcare laws and regulations (e.g., Affordable Care Act, Inflation Reduction Act of 2022, Loper decision) could adversely affect drug pricing, reimbursement, and overall profitability.
• Product Liability Claims: Exposure to product liability claims from the use of drug candidates in clinical studies and commercial sales, potentially leading to substantial liability, costs, reputational damage, and withdrawal of regulatory approvals.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Reliance on Third-Party Manufacturers: Dependence on a limited number of contract manufacturers (e.g., Catalent Pharma Solutions LLC) for critical materials, posing risks of regulatory non-compliance (cGMP), limited capacity, supply interruptions, and delays in qualifying alternative suppliers.
• Reliance on Third-Party Clinical Studies: Dependence on CROs, clinical investigators, and clinical study sites for conducting, supervising, and monitoring clinical trials, with limited direct control over their performance and adherence to Good Clinical Practice (GCP) regulations, potentially leading to delays or termination of studies.
• Trade Secret Disclosure: Sharing proprietary information with third-party collaborators and service providers increases the risk of trade secrets being discovered by competitors or inadvertently disclosed.
• Intellectual Property Protection: Risk of failure to adequately protect or enforce intellectual property rights (patents, trade secrets) globally, including challenges to patent validity or enforceability, and the potential for competitors to circumvent patents.
• Intellectual Property Infringement: Risk of infringing on the intellectual property rights of others, which could result in injunctions, substantial damages, or the inability to develop or commercialize products.
• Licensing Agreement Compliance: Failure to comply with obligations under intellectual property license agreements could lead to the loss of critical license rights.
• Employee/Consultant Misconduct: Exposure to risks of fraud or misconduct by employees, principal investigators, consultants, and commercial partners, including non-compliance with regulatory standards and healthcare fraud and abuse laws.
• Adverse Side Effects: The use of drug candidates may be associated with unforeseen side effects or adverse events, potentially leading to additional studies, halted development, product liability lawsuits, or withdrawal of regulatory approvals.

Financial & Regulatory Risks

Market & Financial Risks:

• Lack of Profitability: Xenetic Biosciences, Inc. has never been profitable and expects to incur significant operating losses, with no assurance of achieving or sustaining profitability.
• Substantial Funding Requirements: Significant additional capital is required to fund clinical trials, regulatory approvals, and commercialization efforts, with the risk that necessary funding may not be available on acceptable terms or at all, leading to delays or termination of development programs.
• Shareholder Dilution: Future equity or convertible debt financings will likely result in dilution for existing stockholders.
• Nasdaq Listing Compliance: Risk of failing to meet Nasdaq Capital Market's continued listing requirements, which could result in delisting of common shares.
• Cash Access Limitations: Market conditions or financial institution failures could impair the Company's ability to access its existing cash, cash equivalents, and investments.
• Non-Cash Charges: Significant non-cash charges, such as share-based payments, may adversely impact reported results of operations.
• Accounting Standard Changes: Potential for new accounting standards or varying interpretations of existing standards to cause adverse fluctuations in financial reporting or require restatements.
• Tax Strategy Limitations: The ability to utilize net operating loss (NOL) carryforwards and tax credits may be substantially limited due to ownership changes (Section 382 of the U.S. Internal Revenue Code) or foreign tax legislation.
• Government Price Controls: Governments in the U.S. and foreign jurisdictions may impose price controls or restrictions on reimbursement, adversely affecting future profitability.

Regulatory & Compliance Risks:

• Lengthy Regulatory Process: The drug development and regulatory approval process is extensive, rigorous, and lengthy, with no guarantee of timely approval or approval for broad indications.
• Post-Approval Regulatory Scrutiny: Approved drug candidates remain subject to ongoing and extensive regulatory requirements for manufacturing, labeling, promotion, and post-marketing surveillance, with non-compliance potentially leading to sanctions or withdrawal of approval.
• Orphan Drug Designation Uncertainty: May not obtain or maintain the benefits associated with orphan drug designation, including market exclusivity.
• Environmental, Health & Safety Compliance: Subject to numerous environmental, health, and safety laws and regulations, with risks of fines, penalties, or significant costs for non-compliance or accidental contamination.
• Information Technology System Failures: Reliance on third-party information technology systems makes the Company vulnerable to physical/electronic break-ins, computer viruses, cybersecurity attacks, and data security incidents, which could disrupt operations and lead to financial and reputational damage.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• DNase Technology: This is the primary focus of Xenetic Biosciences, Inc.'s internal development efforts. The technology is strategically important for its potential to improve outcomes of existing cancer treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs). The Company aims to advance its systemic DNase program into first-in-human clinical studies for locally advanced or metastatic solid tumors, including pancreatic carcinoma and colorectal carcinoma.
• PolyXen Platform: This proprietary drug delivery platform utilizes polysialic acid (PSA) to prolong the half-life and potentially enhance the stability of therapeutic peptides and proteins. While not an active internal development focus in 2024, it remains a valuable asset, generating royalty revenue through licensing.

Innovation Pipeline:

• Systemic DNase Program: The Company is focused on advancing this program towards a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors.
• DNase-Armored CAR T Program: This program is in early pre-clinical development, with the goal of demonstrating that CAR T cells engineered to secrete DNase can enhance the depth and durability of response against solid tumor indications. This is a key area of collaboration with Scripps Research Institute and Belgian Volition SARL Limited.

Intellectual Property Portfolio:

• Patent Strategy: Xenetic Biosciences, Inc. actively seeks to protect its proprietary technology through patent filings in the U.S. and key international pharmaceutical markets (e.g., U.K., Australia, Japan, Canada, South Korea, China, India, Russia, and certain E.U. countries). The strategy focuses on innovations and improvements related to its drug candidates and technologies.
• Patent Holdings: As of February 28, 2025, the Company directly or indirectly owns 35 U.S. and international patents and pending patent applications.
  • XDNASE and XCART Patent Families: These include recently filed applications with expiration dates extending to 2042. They cover the use of DNase for cancer treatment, amelioration of side effects, and the use of certain CAR-T cells (with or without DNase), including those administered with immune checkpoint inhibitors.
  • PolyXen Platform Patents: These patents cover polysialylation and advanced polymer conjugate technologies. While some older patents began expiring in 2021, the remaining PolyXen technology patents expire in 2040. The Company has not renewed these patents for the latter years of their life.
• Trade Secrets & Know-how: The Company also relies on unpatented know-how, technology, and other proprietary information, protected through confidentiality agreements with employees, consultants, and collaborators.

Technology Partnerships:

• Strategic Alliances:
  • University of Virginia: Collaboration to advance the systemic DNase program and investigate DNase I combinations with immunotherapies.
  • Scripps Research Institute: Collaboration for pre-clinical development of DNase technology, including CAR T in vivo models.
  • Belgian Volition SARL Limited: Research and development collaboration to develop NETs-targeted adoptive cell therapies, combining Volition’s Nu.Q® technology with Xenetic Biosciences, Inc.’s DNase-Armored CAR T platform.
  • CLS Therapeutics Ltd.: Exclusive license and sublicense agreements for interventional DNase technology.
  • Takeda Pharmaceutical Co. Ltd.: Sublicense agreement for PolyXen technology, generating royalty revenue.
  • PJSC Pharmsynthez and Serum Institute of India Limited: Collaborative research and development agreements for PolyXen and ImuXen technologies in specific territories.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: On June 19, 2024, Xenetic Biosciences, Inc. entered into separation agreements with its former Chief Executive Officer, Jeffrey F. Eisenberg, and former Chief Scientific Officer, Curtis Lockshin. James Parslow currently serves as both Interim Chief Executive Officer and Chief Financial Officer. The Company's future success is dependent on its ability to retain key executive team members, consultants, and advisors, and to attract and motivate qualified personnel.

Board Composition: The Board of Directors includes Grigory Borisenko, Firdaus Jal Dastoor, Dmitry Genkin, Roger Kornberg, Moshe Mizrahy, and Alexey Vinogradov. Dr. Dmitry Genkin is a significant shareholder of PeriNess Ltd., and Mr. Moshe Mizrahy is a majority shareholder and director of PeriNess Ltd., with which the Company has a clinical trial services agreement. Allan Tsung, MD, Chair of the Department of Surgery at the University of Virginia School of Medicine, is a member of the Company’s Scientific Advisory Board.

Human Capital Strategy

Workforce Composition:

• Total Employees: 2 full-time employees (as of December 31, 2024).
• Geographic Distribution: Not explicitly detailed, but the Company maintains a 401(k) savings plan for U.S. employees.
• Skill Mix: To supplement its limited internal staff, Xenetic Biosciences, Inc. utilizes specialists in regulatory affairs, pharmacovigilance, process engineering, manufacturing, quality assurance, preclinical and clinical development, accounting, and business development, including scientific advisors and independent consultants.

Talent Management: Acquisition & Retention:

• Hiring Strategy: The Company faces intense competition for skilled personnel in the biotechnology sector.
• Retention Metrics: Not disclosed.
• Employee Value Proposition: The Company offers a defined contribution 401(k) savings plan for U.S. employees, with Company contributions of approximately $31,000 in 2024 and $41,000 in 2023.

Diversity & Development: Not explicitly disclosed in the filing. Culture & Engagement: Not explicitly disclosed in the filing.

Environmental & Social Impact

Environmental Commitments:

• Climate Strategy: Not explicitly disclosed in the filing.
• Supply Chain Sustainability: Not explicitly disclosed in the filing.

Social Impact Initiatives:

• Community Investment: Not explicitly disclosed in the filing.
• Product Impact: Not explicitly disclosed in the filing.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Not explicitly disclosed in the filing.
• Economic Sensitivity: The Company's financial condition, results of operations, business, and cash flow are susceptible to negative impacts from general global economic conditions and financial market instability. This includes disruptions from public health epidemics (e.g., COVID-19), international conflicts (e.g., Ukraine, Middle East), terrorism, or other geopolitical events, and associated sanctions.
• Industry Cycles: Not explicitly disclosed in the filing.

Planning & Forecasting: Not explicitly disclosed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• U.S. Regulation: Xenetic Biosciences, Inc. is subject to extensive regulation by the U.S. Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (FDCA) and the Public Health Service Act (PHSA) for its drug and biologic candidates. This includes requirements for preclinical testing (Good Laboratory Practices - GLP), Investigational New Drug (IND) applications, human clinical trials (Good Clinical Practice - GCP, Institutional Review Board - IRB approval, Phase I/II/III), New Drug Applications (NDA) or Biologics License Applications (BLA), compliance with current Good Manufacturing Practices (cGMP), FDA inspections, and comprehensive post-approval requirements (e.g., Phase IV studies, Risk Evaluation and Mitigation Strategies - REMS, adverse event reporting, labeling, advertising, and promotion).
• Foreign Regulation: The Company is also subject to varying regulatory requirements in other jurisdictions, including the European Union, for clinical trials (e.g., Clinical Trial Applications - CTA), product approval, licensing, pricing, and reimbursement. Foreign regulations may offer market exclusivity periods, such as 8 years of data exclusivity plus 2 years of market exclusivity for new chemical entities in the EU, and 10 years of market exclusivity for orphan products.
• Orphan Drug Act: The Company intends to pursue orphan drug designation, which provides incentives and potentially a seven-year exclusive marketing period in the U.S. for drugs treating rare diseases.
• Pediatric Information: Compliance with the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA) may be required, potentially offering additional market exclusivity. The Food and Drug Administration Safety and Innovation Act (FDASIA) requires a Pediatric Study Plan (PSP).
• Expedited Development and Review Programs: The Company may be eligible for and pursue expedited programs such as Fast Track, Priority Review, Accelerated Approval, Breakthrough Therapy Designation, and the Regenerative Medicine Advanced Therapy (RMAT) program to accelerate development and review.
• Other Regulatory Matters: Beyond the FDA, the Company's activities are subject to regulation by various U.S. federal and state authorities (e.g., Centers for Medicare & Medicaid Services, Department of Health and Human Services, Drug Enforcement Administration, Federal Trade Commission) concerning sales, marketing, fraud and abuse laws, data privacy, and pricing/reimbursement programs (e.g., Medicaid Drug Rebate Program, Medicare Parts B and D, Federal Supply Schedule).
• Healthcare Reform: Recent legislative actions, including the Affordable Care Act (ACA) and the Inflation Reduction Act of 2022 (which allows Medicare to negotiate drug prices and imposes inflation-based rebates), could significantly impact drug pricing and reimbursement. The U.S. Supreme Court's Loper decision overturning the Chevron doctrine may lead to increased judicial scrutiny of agency regulations, potentially altering how healthcare laws are applied.

Trade & Export Controls:

• Sanctions Compliance: The Company acknowledges that geopolitical events, such as the conflicts in Ukraine and the Middle East, and associated sanctions and export controls, could adversely impact its business and operations.

Legal Proceedings: As of December 31, 2024, there are no material legal proceedings that, in the opinion of management, are reasonably likely to have a material adverse effect on the Company's financial position, results of operations, or cash flows.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: Xenetic Biosciences, Inc. has incurred substantial losses since its inception and has provided a full valuation allowance on its deferred tax assets, indicating that it is more likely than not that these assets will not be realized. Consequently, there was no income tax provision (benefit) for the years ended December 31, 2024, and 2023.
• Geographic Tax Planning: The Company files income tax returns in the U.S. federal and Massachusetts state tax jurisdictions, as well as in foreign tax jurisdictions including the U.K., Germany, and Switzerland.
• Tax Reform Impact: The Tax Cuts and Jobs Act (TCJA) changed federal deferred tax values and utilization rules for Net Operating Loss (NOL) carryforwards. The Inflation Reduction Act of 2022 may also impact tax considerations. The Company's estimates of effective tax rates and income tax assets/liabilities are subject to potential changes in tax laws, regulations, and interpretations.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Xenetic Biosciences, Inc. maintains workers’ compensation insurance to cover costs and expenses related to employee injuries, including those resulting from the use of hazardous materials.
• Risk Transfer Mechanisms: The Company does not carry a specific insurance policy to mitigate the risk of accidental contamination or injury from hazardous materials to itself or the environment. Beyond workers' compensation, other risk transfer mechanisms are not explicitly detailed in the filing.